These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 22633209)

  • 21. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel anticoagulants and laboratory testing.
    Eby C
    Int J Lab Hematol; 2013 Jun; 35(3):262-8. PubMed ID: 23590653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Steurer J
    Praxis (Bern 1994); 2014 Aug; 103(17):1032. PubMed ID: 25146949
    [No Abstract]   [Full Text] [Related]  

  • 26. New directions in anticoagulation.
    Alpert JS
    Am J Med; 2012 Mar; 125(3):217-8. PubMed ID: 22340912
    [No Abstract]   [Full Text] [Related]  

  • 27. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral anticoagulants: the move beyond warfarin.
    Frei J; Carroll VS
    J Neurosci Nurs; 2014 Oct; 46(5):253-5. PubMed ID: 25188682
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 31. [Bleeding complications under oral anticoagulation].
    Beyer-Westendorf J
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2491-3. PubMed ID: 25376450
    [No Abstract]   [Full Text] [Related]  

  • 32. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):997-1001. PubMed ID: 25392439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
    Renda G; De Caterina R
    Vascul Pharmacol; 2013; 59(3-4):53-62. PubMed ID: 23872195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
    Gehrie E; Tormey C
    Arch Pathol Lab Med; 2015 May; 139(5):687-92. PubMed ID: 25927153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of new oral anticoagulants in interventional cardiology].
    Brasselet C; Duval S
    Ann Cardiol Angeiol (Paris); 2012 Dec; 61(6):453-6. PubMed ID: 23102941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.